Abstract
Objective: To describe the clinical and subclinical characteristics and evaluate the efficacy of conduction system pacing in the treatment of patients with bradyarrhythmia at Hue Central Hospital. Subjects and Methods: A cross-sectional descriptive study was conducted on 64 patients indicated for conduction system pacing at Hue Central Hospital from January 2026 to July 2026. Data were collected regarding demographic characteristics, reasons for admission, comorbidities, technical parameters of conduction system pacing (pacing threshold, sensing, LVAT, RV6-V1, and paced QRS duration), and procedure-related complication rates. Results: The mean age of the subjects was 60,72 ± 18,47 years, with an equal male-to-female ratio (50%). The primary reasons for hospital admission were chest fatigue (65,63%) and syncope (15,63%). The most common comorbidities included hypertension (51,56%), heart failure (43,75%), and coronary artery disease (35,94%). Dual-chamber pacemaker implantation predominated significantly at 95,31%. Ventricular lead parameters achieved optimal outcomes with a low pacing threshold (1,04 ± 0,1620V) and high sensing amplitude (9,00 ± 2,3401mV). Physiological synchrony was confirmed by a short LVAT (66,98 ± 13,37ms), optimal RV6-V1 duration (40,42 ± 12,40ms), and a narrow paced QRS duration (112,53 ± 8,70ms). No complications were recorded during the procedure. Conclusion: Conduction system pacing is a safe and highly effective interventional method for patients with bradyarrhythmia. This technique helps re-establish synchronous electrical activation between the two ventricles via natural physiological mechanisms with a high success rate and no procedure-related complications.
